Carbonic Anhydrase Inhibitors and Depression
A recent study published in Ophthalmology Science found a significant link between the use of topical carbonic anhydrase inhibitors (CAIs) —a type of eye drop used to treat glaucoma—and an increased risk of developing depression and anxiety. While these eye drops are applied locally, the body can absorb some of the medication into the bloodstream, potentially leading to systemic side effects. The study, which analyzed data from over 17,000 patients, revealed that those using CAI eye drops were more likely to: Be diagnosed with new-onset depression . Start taking antidepressant medications . Experience anxiety disorders within the first year of treatment. Researchers noted that the risk was highest in the first few months of use. However, they also cautioned that the findings might be influenced by the severity of a patient's glaucoma rather than the medication itself, as CAIs are often prescribed when other treatments aren't enough. They recommend that doctors monitor glauc...